Lumos Pharma Inc

Lumos Pharma — FY2020 Earnings Presentation

16 slides from Lumos Pharma's earnings presentation, Mar 9, 2021

  1. Slide 1: Full Year 2020 Financial Results and Corporate Update

    Full Year 2020 Financial Results and Corporate Update March 9, 2021

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within the meaning of The Private Securities Litigat

  3. Slide 3: Lumos Pharma Full Year 2020 Conference Call Agenda

    3 Lumos Pharma Full Year 2020 Conference Call Agenda • Lisa Miller, Director of Investor Relations • Rick Hawkins, CEO • Eugene Kennedy, MD, Outgoing CMO • Carl Langren, CFO • John McKew, PhD, COO & CSO

  4. Slide 4: Overview of Company

    Overview of Company 4 Novel therapeutic asset, LUM-201, with validating Phase 2b OraGrowtH210 Trial in Pediatric Growth Hormone Deficiency (PGHD) Late-stage Rare Disease Asset Initial indication targeted over $1B*, with potential to disrupt current treatment regimen for significant subset of patient

  5. Slide 5: Clinical Development Highlights

    • LUM-201 Trials in PGHD - Phase 2b OraGrowtH210 Trial initiated Q4 2020 - PK/PD OraGrowtH212 Trial to be initiated shortly - Long-term Extension OraGrowtH211 Trial introduced • LUM-201 Opportunity Beyond PGHD - Potential to evaluate LUM-201 in other GHD indications treated by rhGH • Data Publicatio

  6. Slide 6: PRV sale proceeds and pipeline expansion

    • Final tranche of $26 million in proceeds from PRV sale received in January 2021 • PRV proceeds represent non-dilutive funds available for pipeline expansion • Continue pursuit of additional rare disease assets to broaden portfolio Corporate Update 6

  7. Slide 7: PGHD and Standard of Care

    PGHD • Inadequate secretion of growth hormone by pituitary gland during childhood • Hereditary or acquired, although majority of cases are idopathic • Lack of physical growth and numerous metabolic processes also affected • Incidence ≈ 1:3500 PGHD and Standard of Care 2 Rosenfeld 2008 Endocrine Prac

  8. Slide 8: LUM-201 Mechanism of Action

    • Oral LUM-201 is a growth hormone (GH) secretagogue • Acts as an agonist of GH Secretagogue Receptor (GHSR1a) to stimulate GH release1 • LUM-201 has been observed to increase the amplitude of endogenous pulsatile GH secretion2,3 • LUM-201’s stimulatory effect is regulated by GH/IGF-1 feedback LUM-2

  9. Slide 9: Targeted PGHD Population

    Targeted PGHD Population HP-GH hypothalamic-pituitary-growth hormone 1 Blum, et al, Corroboration of Height Velocity Prediction Markers for rhGH with an Oral GH Secretagogue Treatment with Children with GHD, Journal of Endocrine Society, Feb 2021. bvab029, https://doi.org/10.1210/jendso/bvab0299 PEM

  10. Slide 10: Journal Publications and ENDO 2021 Presentation

    • Journal of the Endocrine Society Publications, February 2021 - Development of a Predictive Enrichment Marker for Oral GH Secretagogue LUM-201 in Children with Growth Hormone Deficiency, by Bright, G., et al; bvab029, https://doi.org/10.1210/jendso/bvab029 - Corroboration Between Predictive Enrichm

  11. Slide 11: OraGrowtH210 Trial in PGHD: Clinical Development Outline

    Main Objectives for OraGrowth210 Trial: • Prospectively confirm utility of PEM strategy • Confirm repeatability of PEM classification • Determine optimal dose for Phase 3 trial OraGrowtH210 Trial Sites: • 40-50 trial sites US & International • Academic centers & private clinics OraGrowtH210 Trial Re

  12. Slide 12: PK/PD Response Supports Proposed Doses in PGHD

    • Dose response to 5.6 mg/kg PGHD dose equivalent* • PD plateau possible ≥ 2.8 mg/kg PGHD dose equivalent* PK/PD Response Supports Proposed Doses in PGHD Merck Study 001 in healthy adult subjects *Dose equivalence is based on AUC12 Pharmacokinetics Pharmacodynamics 0 2 4 6 8 0 20 40 60 80 Time (hr)

  13. Slide 13: OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD

    Purpose of OraGrowtH212 Trial: • Further explore LUM-201’s mechanism of amplification of natural pulsatile secretion of growth hormone • To expand data package in support of future regulatory filings OraGrowtH212 Trial Site: • San Borja Arriaran Hospital, Santiago, Chile OraGrowtH212 Trial Timeline:

  14. Slide 14: LUM-201 Program Pipeline

    LUM-201 Program Pipeline *In a subset of patients selected by Predictive Enrichment Markers14 Company plans to target other indications for LUM-201 beyond PGHD and pursue acquisitions and collaborations to expand pipeline beyond LUM-201 Pre-Clinical Phase 1 Phase 2 Phase 3 Status LUM-201 (Ibutamoren

  15. Slide 15: Secure Cash Position

    Metric Position Cash balance December 31, 2020 $98.7 million1 Additional non-dilutive resources Final tranche of $26 million proceeds from PRV sale received in January 2021 Projected cash use per quarter through 2021 ~ $8 to $9 million Shares outstanding as of December 31, 2020 ~ 8.3 million Secure

  16. Slide 16: Lumos Pharma: Summary of Investment Thesis

    • Lead program, LUM-201, with potential to be the first oral growth hormone secretagogue therapy for PGHD • Opportunity to disrupt established and sizable injectable market in PGHD and other indications • Management team with extensive experience in the clinical advancement of rare disease therapeut

Lumos Pharma — FY2020 Earnings Presentation on 6ix